CellSource CoTSE:4880 -2.15%69 EBITDA Margin % is 11.10% as of Apr. 2026, which is 56% below its 10-year median of 25.43. GuruFocus rates TSE:4880 with a GF Score™ of 69/100 and a GF Value™ of 円781.48 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 936 Biotechnology companies, CellSource Co ranks better than 74.57% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. CellSource Co's EBITDA for the
six
months ended in Apr. 2026 was 円197 Mil. CellSource Co's Revenue for the
six
months ended in Apr. 2026 was 円1,776 Mil. Therefore, CellSource Co's EBITDA margin for the quarter that ended in Apr. 2026 was 11.10%.
CellSource Co (TSE:4880) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
CellSource Co EBITDA Margin % Related Terms
CellSource Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for CellSource Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4880 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, CellSource Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellSource Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CellSource Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where CellSource Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellSource Co (TSE:4880) has a EBITDA Margin % of 11.10% as of Apr. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CellSource Co and its competitors. This is 56% below median its historical median of 25.43. Over the past decade, CellSource Co's EBITDA Margin % has ranged from 8.34 to 38.12. According to the industry distribution chart, CellSource Co ranks #238 out of 936 companies in the Biotechnology industry, placing it in the top 25.4%.
Is CellSource Co's EBITDA Margin % too high?
CellSource Co's current EBITDA Margin % of 11.10% is 56% below median its 10-year median of 25.43. Over the past 10 years, this metric has ranged from a low of 8.34 to a high of 38.12. Based on the distribution chart, CellSource Co ranks #238 out of 936 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CellSource Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CellSource Co ranks #238 out of 936 companies for EBITDA Margin %. This puts CellSource Co in the upper half of its industry. Historically, CellSource Co's own EBITDA Margin % has ranged from 8.34 to 38.12 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CellSource Co and its competitors. CellSource Co's current EBITDA Margin % is 11.10%, which is 56% below median its own 10-year median of 25.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円781.48, compared to a current price of 円319.00 — trading 59.2% below its estimated fair value. The current EBITDA Margin % is 11.10%, which is 56% below median its 10-year median of 25.43. CellSource Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current EBITDA Margin % is 11.10% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellSource Co (TSE:4880) Overvalued in 2026?
Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued.
The current stock price of 円319.00 is trading 59.2% below its estimated GF Value™ of 円781.48.
GuruFocus considers CellSource Co to be Significantly Undervalued.
Key valuation signals for TSE:4880:
EBITDA Margin %: 11.10% (56% below median its 10-year median of 25.43)
GF Value™: 円781.48 vs. price of 円319.00 (59.2% below fair value)
No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
69GF Score
Get the complete analysis for TSE:4880
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4880 has been successfully added to your 
